DDInter1050 DDInter1376
Levobunolol is a cyclic ketone that is 3,4-dihydronaphthalen-1-one substituted at position 5 by a 3-(tert-butylamino)-2-hydroxypropoxy group (the S-enantiomer). A non-selective beta-adrenergic antagonist used (as its hydrochloride salt) for treatment of glaucoma. It has a role as an antiglaucoma drug and a beta-adrenergic antagonist. It is a propanolamine, a cyclic ketone and an aromatic ether. It is a conjugate acid of a levobunolol(1+). It derives from a hydride of a tetralin.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levobunolol {u} (Compound) resembles {v} (Compound) Propranolol
Levobunolol {u} may lead to a major life threatening interaction when taken with {v} Salbutamol
Levobunolol {u} (Compound) resembles {v} (Compound) Carteolol
Levobunolol {u} (Compound) treats {v} (Disease) glaucoma
Levobunolol {u} (Compound) binds {v} (Gene) ADRB1
Levobunolol {u} (Compound) upregulates {v} (Gene) SSBP2
Levobunolol {u} (Compound) downregulates {v} (Gene) BAG3
Levobunolol {u} (Compound) causes {v} (Side Effect) Eyelid ptosis
Levobunolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadodiamide
Levobunolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gadoxetic acid
Levobunolol (Compound) resembles Propranolol (Compound)
Levobunolol may lead to a major life threatening interaction when taken with Salbutamol
Levobunolol (Compound) resembles Carteolol (Compound)
Levobunolol (Compound) treats glaucoma (Disease)
Levobunolol (Compound) binds ADRB1 (Gene)
Levobunolol (Compound) upregulates SSBP2 (Gene)
Levobunolol (Compound) downregulates BAG3 (Gene)
Levobunolol (Compound) causes Eyelid ptosis (Side Effect)
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadodiamide
Levobunolol may cause a moderate interaction that could exacerbate diseases when taken with Gadoxetic acid